Please login to the form below

Not currently logged in
Email:
Password:

Idea Pharma adds to its medical investigation team

Appoints Partha Ghosh from Parexel and Peter Wootton from AstraZeneca

Idea Pharma Peter WoottonIdea Pharma has boosted its medical investigation team with the appointment of Partha Ghosh and Peter Wootton.

Former AstraZeneca's medical affairs scientist Wootton and Ghosh, who was previously a director at Parexel, add clinical and regulatory design expertise to the phase II strategy consultants.

Prior to joining Idea Pharma, Wootton (pictured) spend two and a half years at AstraZeneca specialising first in neuroscience and more recently in diabetes. Before that he worked at Grunenthal UK in scientific liaison and advisory roles.

He said: “Time after time I have seen great molecules fail within pharma because they all seem to follow the same formulaic processes and fixate on the obvious paths to market … no two molecules are the same and therefore they need to be treated differently! The obvious path is not always the right path. This is where Idea is different!”

Meanwhile, Ghosh's previous roles include serving as a principal consultant within Parexel's consulting arm.

Commenting on his appointment Ghosh said: “The industry faces its toughest challenge to date. Changing the way it works and ultimately how it thinks is no easy task, yet Idea Pharma is one company that is making serious waves.

“They have been on my radar for a number of years now as a company that is injecting innovation and creativity into early stage molecule/product development. I am keen to work alongside the Idea team and the new breed of clients that they seem to attract, ones that fully understand what it means to be truly innovative.”

12th November 2012

From: Sales, Marketing, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...